Clinical Trials Logo
  1. Home
  2. Malignant Lymphoma
  3. NCT02678299

Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study

Malignant Lymphoma Clinical Trial

Official title:
Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study

Clinical Trial Summary

This is a phase 1/2 open label study to assess the safety and efficacy of pixantrone in combination with bendamustine, etoposide and , for CD20 positive B-cell lymphomas, rituximab (P[R]EBEN), in patients with relapsed aNHL of B- or T-cell phenotype.

Clinical Trial Description

This is a phase 1/2 open label study to assess the safety and efficacy of pixantrone in combination with bendamustine, etoposide and , for CD20 positive B-cell lymphomas, rituximab (P[R]EBEN), in patients with relapsed aNHL of B- or T-cell phenotype. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02678299
Study type Interventional
Source University of Aarhus
Contact
Status Active, not recruiting
Phase Phase 1/Phase 2
Start date February 2016
Completion date December 2025
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03346096 - TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) for AutoSCT in Lymphoma Phase 2
Completed NCT05190263 - Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma
Completed NCT01473095 - Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma Phase 1
Completed NCT00683046 - T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies Phase 2
Recruiting NCT02131688 - Phase I Study of Mitoxantrone Hydrochloride Liposome Injection Phase 1
Completed NCT00892502 - Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? N/A
Completed NCT00685997 - Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas N/A
Not yet recruiting NCT06358001 - EchoTip AcuCore Post-Market Clinical Study
Recruiting NCT04986293 - CPAP or BiPAP for Motion Mitigation During Radiotherapy N/A
Completed NCT01588548 - Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma Phase 1
Withdrawn NCT04464889 - HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation Phase 1
Completed NCT03316144 - Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma Phase 1
Terminated NCT01016795 - Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma Phase 2
Completed NCT04464590 - Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT
Recruiting NCT04698616 - Lean Body Mass and Side Effects in Patients With Lymphoma
Completed NCT01499147 - Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies N/A
Completed NCT01789060 - p-AKT Expression on Clinical Outcomes in Malignant Lymphoma N/A
Completed NCT05827341 - A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials
Active, not recruiting NCT05515029 - Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis Phase 3
Not yet recruiting NCT05545202 - A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation Phase 4